{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
USAN:COBNABEXAGENE ANVUPARVOVEC HEXA [USAN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:duvalgagene otiparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03199469: Phase 2/Phase 3 Interventional Active, not recruiting X-Linked Myotubular Myopathy
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:ixoberogene soroparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:bevufenogene nofeparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:clemidsogene lanparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03517085: Phase 1/Phase 2 Interventional Completed GSD1
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03584165: Phase 3 Interventional Enrolling by invitation Choroideremia
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04566445: Phase 2 Interventional Terminated Dry Age-related Macular Degeneration
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:domofenogene zalfaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE